Modulator Role of Oral Antidiabetic Metformin on Intestinal Microbiota


Creative Commons License

Bugdayci A. Y. , ULUDAĞ M. O.

GAZI MEDICAL JOURNAL, vol.31, no.4, pp.696-699, 2020 (ESCI) identifier identifier

  • Publication Type: Article / Review
  • Volume: 31 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.12996/gmj.2020.162
  • Journal Name: GAZI MEDICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier
  • Page Numbers: pp.696-699
  • Gazi University Affiliated: Yes

Abstract

Metformin (1,1-dimethylbiguanidhydrochloride) is widely used as a first-line treatment for type 2 diabetes mellitus (T2DM) and is the most prescribed antidiabetic drug in the USA. Metformin has been shown to inhibit liver glucose production, regulate peripheral glucose uptake in both liver and skeletal muscle, and increase insulin sensitivity. Even though metformin is thought tohave an anti-hyperglycemic effect bysuppressing the hepatic glucose output through activation of adenosinemonophosphate (AMP)-activated protein kinase (AMPK) dependent and AMPK independent pathways in the liver, studies reveal that it may also act through pathways in the intestine. Microbiota-mediated effects of metformin, which are claimed to be the cause of both therapeutic and adverse effects and the mechanisms of these effects have been investigated based on currentarticles on the subject.